Targeting Aberrant Transcriptional Repression in Acute Myeloid Leukemia

Reviews in Clinical and Experimental Hematology

Volumn 7, Issue 2, 2003, Pages 139-159

  Moe Behrens, Gerd H G ^a   Pandolfi, Pier Paolo ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 CARBOXYCINNAMIC ACID BISHYDROXIC ACID; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; APICIDIN; AZACITIDINE; BENZAMIDE DERIVATIVE; BUTYRIC ACID DERIVATIVE; CL 994; DEPSIPEPTIDE; DEPUDECIN; FR 901228; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; HYDROXAMIC ACID; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NICOTINAMIDE; OXAMFLATIN; PROXAMIDE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR; SODIUM PHENYLBUTYRATE; SPLITOMYCIN; TETRAPEPTIDE; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BETA THALASSEMIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CARCINOGENESIS; CARDIOTOXICITY; CELL CYCLE; CELL DIFFERENTIATION; CHEMOTHERAPY INDUCED EMESIS; CHROMATIN; CHROMATIN STRUCTURE; CHROMOSOME 11; CHROMOSOME 17; CHROMOSOME 5; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DNA BINDING; DNA METHYLATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ECG ABNORMALITY; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; LEUKEMOGENESIS; LIGAND BINDING; MULTIDRUG RESISTANCE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PATHOGENESIS; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; PROTEIN INTERACTION; REVIEW; SIDE EFFECT; T CELL LYMPHOMA; TERATOGENICITY; THROMBOCYTOPENIA; TRANSCRIPTION INITIATION; TREATMENT OUTCOME;

ACETYLTRANSFERASES; ACUTE DISEASE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOID; TRANSCRIPTION, GENETIC;

EID: 0344845184     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. DeRisi JL, Iyer VR, Brown PO. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 278: 680-686, 1997.
2. Holstege FC, Jennings EG, Wyrick JJ, et al. Dissecting the regulatory circuitry of a eukaryotic genome. Cell, 95: 717-728, 1998.
3. Brown PO and Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet, 21: 33-37, 1999.
4. Schwaller J, Parganas E, Wang D, et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6: 693-704, 2000.
5. Pandolfi PP. Transcription therapy for cancer. Oncogene, 20: 3116-3127, 2001.
6. Kornberg RD and Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell, 98: 285-294, 1999.
7. Gregory PD, Wagner K, Horz W. Histone acetylation and chromatin remodeling. Exp Cell Res, 265: 195-202, 2001.
8. Davie JR. Covalent modifications of histones: expression from chromatin templates. Curr Opin Genet Dev, 8: 173-178, 1998.
9. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem, 70: 81-120, 2001.
10. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer, 1: 194-202, 2001.
11. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov, 1: 287-299, 2002.
12. Luger K, Mader AW, Richmond RK, et al. Crystal structure of the nudeosome core particle at 2.8 A resolution. Nature, 389: 251-260, 1997.
13. Strahl BD and Allis CD. The language of covalent histone modifications. Nature, 403: 41-45, 2000.
14. Jenuwein T and Allis CD. Translating the histone code. Science, 293: 1074-1080, 2001.
15. Marmorstein R and Roth SY. Histone acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev, 11: 155-161, 2001.
16. Sterner DE and Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev, 64: 435-459, 2000.
17. Flaus A and Owen-Hughes T. Mechanisms for ATP-dependent chromatin remodelling. Curr Opin Genet Dev, 11: 148-154, 2001.
18. Marks PA, Richon VM, Breslow R, et al. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol, 13: 477-483, 2001.
19. Khochbin S, Verdel A, Lemercier C, et al. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev, 11: 162-166, 2001.
20. Deckert J and Struhl K. Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol CeU Biol, 21: 2726-2735, 2001.
21. Gray SG and Ekstrom TJ. The human histone deacetylase family. Exp Cell Res, 262: 75-83, 2001.
22. Di Croce L, Raker VA, Corsaro M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science, 295: 1079-1082, 2002.
23. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene, 20: 3139-3155, 2001.
24. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol, 20: 6891-6903, 2000.
25. Cai RL, Yan-Neale Y, Cueto MA, et al. HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G2/M checkpoint Rad proteins. J Biol Chem, 275: 27909-27916, 2000.
26. Robertson KD, Ait-Si-Ali S, Yokochi T, et al. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet, 25: 338-342, 2000.
27. Smimov DA, Hou S, Ricciardi RP. Association of histone deacetylase with COUP-TF in tumorigenic Adl2-transformed cells and its potential role in shut-off of MHC class I transcription. Virology, 268: 319-328, 2000.
28. Fischle W, Kiermer V, Dequiedt F, et al. The emerging role of class II histone deacetylases. Biochem Cell Biol, 79: 337-348, 2001.
29. Landry J, Sutton A, Tafrov ST, et al. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Nati Acad Sci USA, 97: 5807-5811, 2000.
30. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun, 273: 793-798, 2000.
31. Melnick A and Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167-3215, 1999.
32. He LZ, Merghoub T, Pandolfi PP. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene, 18: 5278-5292, 1999.
33. Mielnicki LM, Ying AM, Head KL, et al. Epigenetic regulation of gelsolin expression in human breast cancer cells. Exp Cell Res, 249: 161-176, 1999.
34. Arnould C, Philippe C, Bourdon V, et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet, 8: 1741-1749, 1999.
35. Licht JD, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood, 85: 1083-1094, 1995.
36. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J, 10: 940-954, 1996.
37. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet, 18: 126-135, 1998.
38. Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature, 391: 811-814, 1998.
39. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature, 391: 815-818, 1998.
40. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature, 389: 349-352, 1997.
41. Smith MA, Parkinson DR, Cheson BD, et al. Retinoids in cancer therapy. J Clin Oncol, 10: 839-864, 1992.
42. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA, 97: 10173-10178, 2000.
43. Koken MH, Daniel MT, Gianni M, et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene, 18: 1113-1118, 1999.
44. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature, 393: 386-389, 1998.
45. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res, 72: 141-196, 1998.
46. Licht JD. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene, 20: 5660-5679, 2001.
47. Ferrara FF, Fazi F, Bianchini A, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res, 61: 2-7, 2001.
48. Wang J, Hoshino T, Redner RL, et al. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction. with the human -N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA, 95: 10860-10865, 1998.
49. Wang J, Saunthararajah Y, Redner RL, et al. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res, 59: 2766-2769, 1999.
50. Minucci S, Nervi C, Lo Coco F, et al. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene, 20: 3110-3115, 2001.
51. Heibert SW, Lutterbach B, Durst K, et al. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins. Cancer Chemother Pharmacol, 48 Suppl 1: S31-34, 2001.
52. Goodman RH and Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev, 14: 1553-1577, 2000.
53. Liang J, Prouty L, Williams BJ, et al. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood, 92: 2118-2122, 1998.
54. Panagopoulos I, Fioretos T, Isaksson M, et al. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum Mol Genet, 10: 395-404, 2001.
55. Dervan PB and Burli RW. Sequence-specific DNA recognition by polyamides. Curr Opin Chem Biol 3: 688-693, 1999.
56. Mapp AK, Ansari AZ, Ptashne M, et al. Activation of gene expression by small molecule transcription factors. Proc Natl Acad Sci USA, 97: 3930-3935, 2000.
57. Liu PQ, Rebar EJ, Zhang L, et al. Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J Biol Chem, 276: 11323-11334, 2001.
58. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401: 188-193, 1999.
59. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res, 60: 4561-4572, 2000.
60. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr, 5: 245-253, 1996.
61. Huang L and Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med, 6: 849-866, 2000.
62. Lu J, McKinsey TA, Zhang CL, et al. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol Cell, 6: 233-244, 2000.
63. Bernstein BE, Tong JK, Schreiber SL. Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci USA, 97: 13708-13713, 2000.
64. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med, 7: 437-443, 2001.
65. Kwon HJ, Owa T, Hassig CA, et al. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci USA, 95: 3356-3361, 1998.
66. Glick RD, Swendeman SL, Coffey DC, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res, 59: 4392-4399, 1999.
67. Maeda T, Towatari M, Kosugi H, et al. Upregulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood, 96: 3847-3856, 2000.
68. Magner wJ, Kazim AL, Stewart C, et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol, 165: 7017-7024, 2000.
69. Mishra N, Brown DR, Olorenshaw IM, et al. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci USA, 98: 2628-2633, 2001.
70. Shestakova E, Bandu MT, Doly J, et al. Inhibition of histone deacetylation induces constitutive derepression of the beta interferon promoter and confers antiviral activity. J Virol, 75: 3444-3452, 2001.
71. Parsons PG, Hansen C, Fairlie DP, et al. Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem Pharmacol, 53: 1719-1724, 1997.
72. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA, 97: 10014-10019, 2000.
73. Sambucetti LC, Fischer DD, Zabludoff S, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem, 274: 34940-34947, 1999.
74. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays, 17: 423-430, 1995.
75. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA, 96: 4592-4597, 1999.
76. Xiao H, Hasegawa T, Isobe K. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem, 73: 291-302, 1999.
77. Vrana JA, Decker RH, Johnson CR, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene, 18: 7016-7025, 1999.
78. Macleod KF, Sherry N, Hannon G, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev, 9: 935-944, 1995.
79. Sandor V, Senderowicz A, Mertins S, et al. P21-dependent G(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer, 83: 817-825, 2000.
80. Rosato RR, Wang Z, Gopalkrishnan RV, et al. Evidence of a functional role for the cylin-dependent kinase-inhibitor p21WAF1/-CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int J Oncol, 19: 181-191, 2001.
81. Burgess AJ, Pavey S, Warrener R, et al. Upregulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol, 60: 828-837, 2001.
82. Takakura M, Kyo S, Sowa Y, et al. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res, 29: 3006-3011, 2001.
83. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA, 98: 10833-10838, 2001.
84. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab, 12: 294-300, 2001.
85. Suzuki T, Yokozaki H, Kuniyasu H, et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer, 88: 992-997, 2000.
86. Cao XX, Mohuiddin I, Ece F, et al. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol, 25: 562-568, 2001.
87. Haggarty SJ, Koeller KM, Wong JC, et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA, 100: 4389-4394, 2003.
88. Bedalov A, Gatbonton T, Irvine WP, et al. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA, 98: 15113-15118, 2001.
89. Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA, 93: 5703-5708, 1996.
90. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA, 95: 3003-3007, 1998.
91. Kosugi H, Towatari M, Hatano S, et al. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to antileukemia therapy. Leukemia, 13: 1316-1324, 1999.
92. Marks PA, Richon VM, Rifkind RA, Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst, 92: 1210-1216, 2000.
93. Furumai R, Komatsu Y, Nishino N, et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA, 98: 87-92, 2001.
94. Komatsu Y, Tomizaki KY, Tsukamoto M, et al. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res, 61: 4459-4466, 2001.
95. Su GH, Sohn TA, Ryu B, et al. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res, 60: 3137-3142, 2000.
96. Lavoie R, Bouchain G, Frechette S, et al. Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg Med Chem Lett, 11: 2847-2850, 2001.
97. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem, 8: 1505-1511, 2001.
98. Carmen AA, Griffin PR, Calaycay JR, et al. Yeast HOS3 forms a novel trichostatin A-insensitive homodimer with intrinsic histone deacetylase activity. Proc Natl Acad Sci USA, 96: 12356-12361, 1999.
99. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev, 9: 40-48, 1999.
100. Muller C and Leutz A. Chromatin remodeling in development and differentiation. Curr Opin Genet Dev, 11: 167-174, 2001.
101. Melnick- A and Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol, 9: 322-332, 2002.
102. Murray PJ, Kranz M, Ladlow M, et al. The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product apicidin. Bioorg Med Chem Lett, 11: 773-776, 2001.
103. Meinke PT, Colletti SL, Doss G, et al. Synthesis of apicidin-derived quinolone derivatives: parasite-selective histone deacetylase inhibitors and antiproliferative agents. J Med Chem, 43: 4919-4922, 2000.
104. Kijima M, Yoshida M, Sugita K, et al. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem, 268: 22429-22435, 1993.
105. Nakajima H, Kim YB, Terano H, et al. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res, 241: 126-133, 1998.
106. Weidle UH and Grossmann A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res, 20: 1471-1485, 2000.
107. Suzuki T, Ando T, Tsuchiya K, et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem, 42: 3001-3003, 1999.
108. Prakash S, Foster BJ, Meyer M, et al. Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs, 19: 1-11, 2001.
109. He LZ, Bhaumik M, Tribioli C, et al. Two critical hits for promyelocytic leukemia. Mol Cell, 6: 1131-1141, 2000.
110. Kosugi H, Ito M, Yamamoto Y, et al. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-SCID/SCID mice. Jpn J Cancer Res, 92: 529-536, 2001.
111. Byrd JC, Shinn C, Ravi R, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood, 94: 1401-1408, 1999.
112. Warrell RP Jr, He LZ, Richon V, et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst, 90: 1621-1625, 1998.
113. Zhou DC, Kim SH, Ding W, et al. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99: 1356-1363, 2002.
114. Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol, 2: 325-332, 2002.
115. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood, 98: 2865-2868, 2001.
116. Kouraklis G and Theocharis S. Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem Anti-Canc Agents, 2: 477-484, 2002.
117. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res, 8: 718-728, 2002.
118. Dover GJ, Brusilow S, Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med, 327: 569-570, 1992.